Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review

References

• Wang D, Zou L, Jin Q, et al. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018;8(5):699–712. doi: 10.1016/j.apsb.2018.05.005
   PubMed Web of Science ®Google Scholar
• Her L, Zhu HJ. Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab Dispos. 2020;48:230–244. doi: 10.1124/dmd.119.089680
   PubMed Web of Science ®Google Scholar
• Basit A, Neradugomma NK, Wolford C, et al. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol Pharm. 2020;17(11):4114–4124. doi: 10.1021/acs.molpharmaceut.0c00559
   PubMed Web of Science ®Google Scholar
• Wang X, He B, Shi J, et al. Comparative proteomics analysis of human liver microsomes and S9 fractions. Drug Metab Dispos. 2020;48:31–40. doi: 10.1124/dmd.119.089235
   PubMed Web of Science ®Google Scholar
• Li J, Liu S, Shi J, et al. Tissue-specific proteomics analysis of anti-COVID-19 nucleoside and nucleotide prodrug-activating enzymes provides insights into the optimization of prodrug design and pharmacotherapy strategy. ACS Pharmacol Transl Sci. 2021;4(2):870–887. doi: 10.1021/acsptsci.1c00016
   PubMedGoogle Scholar
• Glubb DM, Innocenti F. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med. 2011;3(3):299–313. doi: 10.1002/wsbm.125
   PubMed Web of Science ®Google Scholar
• Chen F, Zhang B, Parker RB, et al. Clinical implications of genetic variation in carboxylesterase drug metabolism. Expert Opin Drug Metab Toxicol. 2018;14(2):131–142. doi: 10.1080/17425255.2018.1420164
   PubMed Web of Science ®Google Scholar
• Wang X, Wang G, Shi J, et al. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J. 2016;16(3):220–230. doi: 10.1038/tpj.2015.42
   PubMed Web of Science ®Google Scholar
• Sanford JC, Wang X, Shi J, et al. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenet Genom. 2016;26(5):197–207. doi: 10.1097/FPC.0000000000000206
   PubMed Web of Science ®Google Scholar
• Fukami T, Nakajima M, Maruichi T, et al. Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genom. 2008;18(10):911–920. doi: 10.1097/FPC.0b013e32830b0c5e
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Kimura T, Ishii M, et al. Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. Biochem Biophys Res Commun. 2008;369(3):939–942. doi: 10.1016/j.bbrc.2008.02.120
   PubMed Web of Science ®Google Scholar
• Rasmussen HB, Madsen MB, Lyauk YK, et al. Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations. Drug Metab Pers Ther. 2017;32(3):163–168. doi: 10.1515/dmpt-2017-0012
   PubMedGoogle Scholar
• Chen BB, Yan JH, Zheng J, et al. Copy number variation in the CES1 gene and the risk of non-alcoholic fatty liver in a Chinese Han population. Sci Rep. 2021;11(1):13984. doi: 10.1038/s41598-021-93549-2
   PubMed Web of Science ®Google Scholar
• Sai K, Saito Y, Tatewaki N, et al. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol. 2010;70(2):222–233. doi: 10.1111/j.1365-2125.2010.03695.x
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Patrick KS, Yuan HJ, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82(6):1241–1248. doi: 10.1016/j.ajhg.2008.04.015
   PubMed Web of Science ®Google Scholar
• Wang X, Rida N, Shi J, et al. A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab Dispos. 2017;45(11):1149–1155. doi: 10.1124/dmd.117.077669
   PubMed Web of Science ®Google Scholar
• Xie C, Ding X, Gao J, et al. The effects of CES1A2 A(−816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genomics. 2014;24(4):204–210. doi: 10.1097/FPC.0000000000000035
   PubMed Web of Science ®Google Scholar
• Zou JJ, Chen SL, Fan HW, et al. CES1A –816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention. J Cardiovasc Pharmacol. 2014;63(2):178–183. doi: 10.1097/FJC.0000000000000037
   PubMed Web of Science ®Google Scholar
• Geshi E, Kimura T, Yoshimura M, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res. 2005;28(9):719–725. doi: 10.1291/hypres.28.719
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Langaee TY, Gong Y, et al. CES1P1 variant –816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. Eur J Clin Pharmacol. 2016;72(6):681–687. doi: 10.1007/s00228-016-2029-x
   PubMed Web of Science ®Google Scholar
• Her L, Shi J, Wang X, et al. Identification of regulatory variants of carboxylesterase 1 (CES1): a proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms. Proteomics. 2023;23(1):e2200176. doi: 10.1002/pmic.202200176
   PubMed Web of Science ®Google Scholar
• Bruxel EM, Salatino-Oliveira A, Genro JP, et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. 2013;13(5):476–480. doi: 10.1038/tpj.2012.25
   PubMed Web of Science ®Google Scholar
• Nelveg-Kristensen KE, Madsen MB, Torp-Pedersen C, et al. Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors. Pharmacogenet Genomics. 2016;26(4):169–177. doi: 10.1097/FPC.0000000000000203
   PubMed Web of Science ®Google Scholar
• Yamada S, Richardson K, Tang M, et al. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J. 2010;10:524–536. doi: 10.1038/tpj.2010.5
   PubMed Web of Science ®Google Scholar
• Wu MH, Chen P, Remo BF, et al. Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics. 2003;13(7):425–435. doi: 10.1097/00008571-200307000-00008
   PubMedGoogle Scholar
• Marsh S, Xiao M, Yu J, et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004;84(4):661–668. doi: 10.1016/j.ygeno.2004.07.008
   PubMed Web of Science ®Google Scholar
• Kubo T, Kim SR, Sai K, et al. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos. 2005;33(10):1482–1487. doi: 10.1124/dmd.105.005587
   PubMed Web of Science ®Google Scholar
• Kim SR, Sai K, Tanaka-Kagawa T, et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos. 2007;35(10):1865–1872. doi: 10.1124/dmd.107.015339
   PubMed Web of Science ®Google Scholar
• Bellott R, Le Morvan V, Charasson V, et al. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol. 2008;61:481–488. doi: 10.1007/s00280-007-0493-9
   PubMed Web of Science ®Google Scholar
• Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity (Edinb). 2010;105(1):4–13. doi: 10.1038/hdy.2010.54
   PubMed Web of Science ®Google Scholar
• Hori T, Hosokawa M. DNA methylation and its involvement in carboxylesterase 1A1 (CES1A1) gene expression. Xenobiotica. 2010;40(2):119–128. doi: 10.3109/00498250903431794
   PubMed Web of Science ®Google Scholar
• Xu J, Yin L, Xu Y, et al. Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels. PLoS One. 2014;9(10):e109663. doi: 10.1371/journal.pone.0109663
   PubMed Web of Science ®Google Scholar
• Wang X, Shi J, Zhu HJ. Functional study of carboxylesterase 1 protein isoforms. Proteomics. 2019;19(4):e1800288.
   PubMed Web of Science ®Google Scholar
• Shen Y, Shi Z, Yan B. Carboxylesterases: pharmacological inhibition regulated expression and transcriptional involvement of nuclear receptors and other transcription factors. Nuclear Receptor Research. 2019;6:101435.
   Google Scholar
• Staudinger JL, Xu C, Cui YJ, et al. Nuclear receptor-mediated regulation of carboxylesterase expression and activity. Expert Opin Drug Metab Toxicol. 2010;6(3):261–271. doi: 10.1517/17425250903483215
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cheng X, Aleksunes L, et al. Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice. Drug Metab Dispos. 2012;40(6):1191–1197. doi: 10.1124/dmd.111.043877
   PubMed Web of Science ®Google Scholar
• Collins JM, Lu R, Wang X, et al. Transcriptional regulation of carboxylesterase 1 in human liver: role of the nuclear receptor subfamily 1 group H member 3 and its splice isoforms. Drug Metab Dispos. 2022;50(1):43–48. doi: 10.1124/dmd.121.000649
   PubMed Web of Science ®Google Scholar
• Zhu W, Song L, Zhang H, et al. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000;28:186–191.
   PubMed Web of Science ®Google Scholar
• Zhang C, Gao P, Yin W, et al. Dexamethasone regulates differential expression of carboxylesterase 1 and carboxylesterase 2 through activation of nuclear receptors. J Huazhong Univ Sci Technolog Med Sci. 2012;32(6):798–805. doi: 10.1007/s11596-012-1037-z
   PubMedGoogle Scholar
• Xiao D, Chen YT, Yang D, et al. Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol. 2012;84(2):232–239. doi: 10.1016/j.bcp.2012.04.002
   PubMed Web of Science ®Google Scholar
• Choi W, Cogdell D, Feng Y, et al. Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006;5(11):1450–1456. doi: 10.4161/cbt.5.11.3271
   PubMed Web of Science ®Google Scholar
• Xiao D, Yang D, Guo L, et al. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug. Br J Pharmacol. 2013;168(8):1989–1999. doi: 10.1111/bph.12125
   PubMed Web of Science ®Google Scholar
• Shang W, Liu J, Chen R, et al. Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells. Xenobiotica. 2016;46(5):393–405. doi: 10.3109/00498254.2015.1082209
   PubMed Web of Science ®Google Scholar
• Xu M, Zhang L, Lin L, et al. Cisplatin increases carboxylesterases through increasing PXR mediated by the decrease of DEC1. J Biomed Res. 2023;37(6):431–447. doi: 10.7555/JBR.37.20230047
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang X, Liu Y, et al. Insulin transcriptionally down-regulates carboxylesterases through pregnane X receptor in an Akt-dependent manner. Toxicology. 2019;422:60–68. doi: 10.1016/j.tox.2019.04.008
   PubMed Web of Science ®Google Scholar
• Maruichi T, Fukami T, Nakajima M, et al. Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). Biochem Pharmacol. 2010;79(2):288–295. doi: 10.1016/j.bcp.2009.08.019
   PubMed Web of Science ®Google Scholar
• Tian X, Yan F, Zheng J, et al. Endoplasmic reticulum targeting ratiometric fluorescent probe for Carboxylesterase 2 detection in drug-induced acute liver injury. Anal Chem. 2019;91(24):15840–15845. doi: 10.1021/acs.analchem.9b04189
   PubMed Web of Science ®Google Scholar
• Zhang C, Xu Y, Gao P, et al. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats. Int Immunopharmacol. 2015;24(2):153–158. doi: 10.1016/j.intimp.2014.12.003
   PubMed Web of Science ®Google Scholar
• Li M, Lan L, Zhang S, et al. IL-6 downregulates hepatic carboxylesterases via NF-kappaB activation in dextran sulfate sodium-induced colitis. Int Immunopharmacol. 2021;99:107920. doi: 10.1016/j.intimp.2021.107920
   PubMed Web of Science ®Google Scholar
• Gao P, Li M, Lu J, et al. IL-33 downregulates hepatic carboxylesterase 1 in acute liver injury via macrophage-derived exosomal miR-27b-3p. J Clin Transl Hepatol. 2023;11:1130–1142. doi: 10.14218/JCTH.2022.00144
   PubMed Web of Science ®Google Scholar
• Yang D, Pearce RE, Wang X, et al. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol. 2009;77(2):238–247. doi: 10.1016/j.bcp.2008.10.005
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Appel DI, Jiang Y, et al. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 2009;37(9):1819–1825. doi: 10.1124/dmd.109.028209
   PubMed Web of Science ®Google Scholar
• Hines RN, Simpson PM, McCarver DG. Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny. Drug Metab Dispos. 2016;44(7):959–966. doi: 10.1124/dmd.115.068957
   PubMed Web of Science ®Google Scholar
• Chen YT, Trzoss L, Yang D, et al. Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: postnatal surge and organ-dependent regulation. Toxicology. 2015;330:55–61. doi: 10.1016/j.tox.2015.02.007
   PubMed Web of Science ®Google Scholar
• Boberg M, Vrana M, Mehrotra A, et al. Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants. Drug Metab Dispos. 2017;45(2):216–223. doi: 10.1124/dmd.116.072652
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Eyler RF, et al. Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms. Basic Clin Pharmacol Toxicol. 2016;119(6):555–561. doi: 10.1111/bcpt.12625
   PubMed Web of Science ®Google Scholar
• Zou LW, Jin Q, Wang DD, et al. Carboxylesterase inhibitors: an update. Curr Med Chem. 2018;25(14):1627–1649. doi: 10.2174/0929867325666171204155558
   PubMed Web of Science ®Google Scholar
• Song YQ, Jin Q, Wang DD, et al. Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism. Chem Biol Interact. 2021;345:109566. doi: 10.1016/j.cbi.2021.109566
   PubMed Web of Science ®Google Scholar
• Takahashi S, Katoh M, Saitoh T, et al. Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos. 2009;37(5):956–961. doi: 10.1124/dmd.108.024331
   PubMed Web of Science ®Google Scholar
• Fukami T, Takahashi S, Nakagawa N, et al. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos. 2010;38(12):2173–2178. doi: 10.1124/dmd.110.034454
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Appel DI, Peterson YK, et al. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology. 2010;270(2–3):59–65. doi: 10.1016/j.tox.2010.01.009
   PubMed Web of Science ®Google Scholar
• Yanjiao X, Chengliang Z, Xiping L, et al. Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro. Drug Metab Pharmacokinet. 2013;28(6):468–474. doi: 10.2133/dmpk.dmpk-12-rg-143
   PubMed Web of Science ®Google Scholar
• Rhoades JA, Peterson YK, Zhu HJ, et al. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm Res. 2012;29(4):972–982. doi: 10.1007/s11095-011-0637-9
   PubMed Web of Science ®Google Scholar
• Zhang C, Xu Y, Zhong Q, et al. In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2. PLoS One. 2014;9(4):e93819. doi: 10.1371/journal.pone.0093819
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fukami T, Nakajima M, et al. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos. 2014;42(7):1103–1109. doi: 10.1124/dmd.114.056994
   PubMed Web of Science ®Google Scholar
• Umehara K, Zollinger M, Kigondu E, et al. Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors. Xenobiotica. 2016;46(10):862–867. doi: 10.3109/00498254.2015.1133867
   PubMed Web of Science ®Google Scholar
• Zhao YS, Qian XK, Guan XQ, et al. Discovery of natural alkaloids as potent and selective inhibitors against human carboxylesterase 2. Bioorg Chem. 2020;105:104367. doi: 10.1016/j.bioorg.2020.104367
   PubMed Web of Science ®Google Scholar
• Zhao T, Wang D, Zhao S, et al. Comparison of the inhibitory effects of clotrimazole and Ketoconazole against human carboxylesterase 2. Curr Drug Metab. 2021;22(5):391–398. doi: 10.2174/1389200222666210210115509
   PubMed Web of Science ®Google Scholar
• Hirosawa K, Fukami T, Nakano M, et al. Evaluation of drug-drug interactions via inhibition of hydrolases by Orlistat, an anti-obesity drug. Drug Metab Dispos. 2023;51(8):1016–1023. doi: 10.1124/dmd.123.001266
   PubMed Web of Science ®Google Scholar
• Xu J, Qiu JC, Ji X, et al. Potential pharmacokinetic herb-drug interactions: have we overlooked the importance of human carboxylesterases 1 and 2? Curr Drug Metab. 2019;20(2):130–137. doi: 10.2174/1389200219666180330124050
   PubMed Web of Science ®Google Scholar
• Qian Y, Markowitz JS. Natural products as modulators of CES1 activity. Drug Metab Dispos. 2020;48(10):993–1007. doi: 10.1124/dmd.120.000065
   PubMed Web of Science ®Google Scholar
• Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genom. 2013;23(1):1–8. doi: 10.1097/FPC.0b013e32835aa8a2
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Holmberg MT, Tornio A, et al. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharm Ther. 2015;97(6):650–658. doi: 10.1002/cpt.101
   PubMed Web of Science ®Google Scholar
• Neuvonen M, Tarkiainen EK, Tornio A, et al. Effects of genetic variants on carboxylesterase 1 gene expression, and clopidogrel pharmacokinetics and antiplatelet effects. Basic Clin Pharmacol Toxicol. 2018;122(3):341–345. doi: 10.1111/bcpt.12916
   PubMed Web of Science ®Google Scholar
• Xiao FY, Luo JQ, Liu M, et al. Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Sci Rep. 2017;7(1):7244. doi: 10.1038/s41598-017-07736-1
   PubMed Web of Science ®Google Scholar
• Mirzaev KB, Osipova DV, Kitaeva EJ, et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019;34(3):20180039. doi: 10.1515/dmpt-2018-0039
   Google Scholar
• Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404–1412. doi: 10.1161/CIRCULATIONAHA.112.001233
   PubMed Web of Science ®Google Scholar
• Zhu Z, Qian C, Su C, et al. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2022;22(1):481. doi: 10.1186/s12872-022-02910-4
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang C, Qi W, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics in healthy Chinese subjects. Pharmgenomics Pers Med. 2021;14:477–485. doi: 10.2147/PGPM.S291723
   PubMed Web of Science ®Google Scholar
• Sychev D, Skripka A, Ryzhikova K, et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020;35:20190029. doi: 10.1515/dmpt-2019-0029
   Google Scholar
• Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018;11:127–137. doi: 10.2147/PGPM.S169277
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Tornio A, Holmberg MT, et al. Effect of carboxylesterase 1 c.428G > a single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015;80(5):1131–1138. doi: 10.1111/bcp.12667
   PubMed Web of Science ®Google Scholar
• Stage C, Jurgens G, Guski LS, et al. The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers. Basic Clin Pharmacol Toxicol. 2017;121(6):487–492. doi: 10.1111/bcpt.12835
   PubMed Web of Science ®Google Scholar
• Ikonnikova A, Rodina T, Dmitriev A, et al. The influence of the CES1 genotype on the pharmacokinetics of enalapril in patients with arterial hypertension. J Pers Med. 2022;12(4):580. doi: 10.3390/jpm12040580
   PubMed Web of Science ®Google Scholar
• Ikonnikova A, Kazakov R, Rodina T, et al. The influence of structural variants of the CES1 gene on the Pharmacokinetics of Enalapril, presumably due to linkage disequilibrium with the Intronic rs2244613. Genes (Basel). 2022;13(12):2225. doi: 10.3390/genes13122225
   PubMed Web of Science ®Google Scholar
• Her LH, Wang X, Shi J, et al. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2021;87(12):4691–4700. doi: 10.1111/bcp.14888
   PubMed Web of Science ®Google Scholar
• Wang X, Her L, Xiao J, et al. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Transl Sci. 2021;14(4):1380–1389. doi: 10.1111/cts.12989
   PubMed Web of Science ®Google Scholar
• Stage C, Dalhoff K, Rasmussen HB, et al. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios. Basic Clin Pharmacol Toxicol. 2019;125(1):54–61. doi: 10.1111/bcpt.13212
   PubMed Web of Science ®Google Scholar
• Stage C, Jurgens G, Guski LS, et al. The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. Br J Clin Pharmacol. 2017;83(7):1506–1514. doi: 10.1111/bcp.13237
   PubMed Web of Science ®Google Scholar
• Brown JT, Beery N, Taran A, et al. Associations between CES1 variants and dosing and adverse effects in children taking methylphenidate. Front Pediatr. 2022;10:958622. doi: 10.3389/fped.2022.958622
   PubMed Web of Science ®Google Scholar
• Oxenbøll M, Kaalund-Jørgensen K, Rasmussen S, et al. Association of Carboxylesterase 1 Gene (CES1) polymorphism with weight loss in children with attention deficit hyperactivity disorder during methylphenidate treatment. J Proteomics & Bioinf. 2017;2:1010.
   Google Scholar
• Hernandez MH, Bote V, Serra LA, et al. CES1 and SLC6A2 genetic variants as predictors of response to methylphenidate in autism spectrum disorders. Pharmgenomics Pers Med. 2022;15:951–957. doi: 10.2147/PGPM.S377210
   PubMed Web of Science ®Google Scholar
• Liu D, Li X, Li X, et al. Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine. Cancer Chemother Pharmacol. 2021;87(5):681–687. doi: 10.1007/s00280-021-04247-9
   PubMed Web of Science ®Google Scholar
• Hamzic S, Kummer D, Milesi S, et al. Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity. Clin Pharmacol Ther. 2017;102(5):796–804. doi: 10.1002/cpt.641
   PubMed Web of Science ®Google Scholar
• Matsumoto N, Kubota Y, Ishida H, et al. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol. 2020;85(6):1119–1128. doi: 10.1007/s00280-020-04087-z
   PubMed Web of Science ®Google Scholar
• Cura Y, Sanchez-Martin A, Marquez-Pete N, et al. Association of single-nucleotide polymorphisms in capecitabine bioactivation pathway with adjuvant therapy safety in colorectal cancer patients. Pharmaceutics. 2023;15(11):2548. doi: 10.3390/pharmaceutics15112548
   PubMed Web of Science ®Google Scholar
• de with M, van Doorn L, Maasland DC, et al. Capecitabine-induced hand-foot syndrome: a pharmacogenetic study beyond DPYD. Biomed Pharmacother. 2023;159:114232. doi: 10.1016/j.biopha.2023.114232
   PubMed Web of Science ®Google Scholar
• Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008;99(8):1239–1245. doi: 10.1038/sj.bjc.6604673
   PubMed Web of Science ®Google Scholar
• de with M, van Doorn L, Kloet E, et al. Irinotecan-induced toxicity: a pharmacogenetic study beyond UGT1A1. Clin Pharmacokinet. 2023;62:1589–1597. doi: 10.1007/s40262-023-01279-7
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Backman JT, Neuvonen M, et al. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. 2012;92(1):68–71. doi: 10.1038/clpt.2012.13
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang X, Gawronski BE, et al. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013;344(3):665–672. doi: 10.1124/jpet.112.201640
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Nguyen JH, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76–84. doi: 10.1016/j.bcp.2016.09.003
   PubMed Web of Science ®Google Scholar
• Yerrakula G, George SG, KK D, et al. Effect of non-synonymous single-nucleotide polymorphism of human carboxyl esterase 1 on the bioactivation of Dabigatran Etexilate. Int J Appl Pharm. 2022:208–213. doi: 10.22159/ijap.2022v14i5.44682
   PubMedGoogle Scholar
• Laizure SC, Chen F, Farrar JE, et al. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation. Drug Metab Pharmacokinet. 2022;47:100479. doi: 10.1016/j.dmpk.2022.100479
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Bavishi C, et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71(13):1474–1482. doi: 10.1016/j.jacc.2018.01.058
   PubMed Web of Science ®Google Scholar
• Jaeschke RR, Sujkowska E, Sowa-Kucma M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. Psychopharmacol (Berl). 2021;238(10):2667–2691. doi: 10.1007/s00213-021-05946-0
   PubMed Web of Science ®Google Scholar
• Lyauk YK, Stage C, Bergmann TK, et al. Population pharmacokinetics of methylphenidate in healthy adults emphasizing novel and known effects of several carboxylesterase 1 (CES1) variants. Clin Transl Sci. 2016;9(6):337–345. doi: 10.1111/cts.12423
   PubMed Web of Science ®Google Scholar
• Xiao J, Shi J, Thompson BR, et al. Physiologically-based pharmacokinetic modeling to predict methylphenidate exposure affected by interplay among carboxylesterase 1 pharmacogenetics, drug-drug interactions, and sex. J Pharmaceut sci. 2022;111(9):2606–2613. doi: 10.1016/j.xphs.2022.04.019
   PubMed Web of Science ®Google Scholar
• Cura Y, Perez-Ramirez C, Sanchez-Martin A, et al. Influence of single-nucleotide polymorphisms on clinical outcomes of capecitabine-based chemotherapy in colorectal cancer patients: a systematic review. Cancers (Basel). 2023;15(6):1821. doi: 10.3390/cancers15061821
   PubMed Web of Science ®Google Scholar
• de Man FM, Goey AKL, van Schaik RHN, et al. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–1254. doi: 10.1007/s40262-018-0644-7
   PubMed Web of Science ®Google Scholar
• Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a determinant of response to Irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107(8): doi: 10.1093/jnci/djv132
   PubMedGoogle Scholar
• Oh J, Lee S, Lee H, et al. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. PLoS One. 2017;12(4):e0176320. doi: 10.1371/journal.pone.0176320
   PubMed Web of Science ®Google Scholar
• Chen Y, Ke M, Xu J, et al. Simulation of the pharmacokinetics of Oseltamivir and its active metabolite in normal populations and patients with hepatic cirrhosis using physiologically based pharmacokinetic modeling. AAPS Pharm Sci Tech. 2020;21(3):98. doi: 10.1208/s12249-020-1638-y
   PubMed Web of Science ®Google Scholar
• Zhang Q, Melchert PW, Markowitz JS. In vitro evaluation of the impact of covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. Chemico-Biological Interactions. 2022;365:110097. doi: 10.1016/j.cbi.2022.110097
   PubMed Web of Science ®Google Scholar
• Zhang F, Li HX, Zhang TT, et al. Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. Chem Biol Interact. 2022;351:109744. doi: 10.1016/j.cbi.2021.109744
   PubMed Web of Science ®Google Scholar
• Patrick KS, Straughn AB, Reeves OT 3rd, et al. Comparative ethanol-induced potentiation of stimulatory responses to dexmethylphenidate versus methylphenidate. J Clin Psychopharmacol. 2015;35(4):464–467. doi: 10.1097/JCP.0000000000000348
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Patrick KS, Straughn AB, et al. Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers. J Clin Psychopharmacol. 2017;37(4):419–428. doi: 10.1097/JCP.0000000000000721
   PubMed Web of Science ®Google Scholar
• Parker RB, Hu ZY, Meibohm B, et al. Effects of alcohol on human carboxylesterase drug metabolism. Clin Pharmacokinet. 2015;54(6):627–638. doi: 10.1007/s40262-014-0226-2
   PubMed Web of Science ®Google Scholar
• Liu W, Yu S, Yan B. Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus. Biochemical Pharmacology. 2022;204:115224. doi: 10.1016/j.bcp.2022.115224
   PubMed Web of Science ®Google Scholar
• Yang B, Parker RB, Meibohm B, et al. Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis. PLoS One. 2022;17(11):e0278111. doi: 10.1371/journal.pone.0278111
   PubMed Web of Science ®Google Scholar
• Ge PX, Jiang LP, Tai T, et al. Short-term standard alcohol consumption enhances platelet response to clopidogrel through inhibition of Nrf2/Ces1 pathway and induction of Cyp2c in mice. Life Sci. 2021;279:119268. doi: 10.1016/j.lfs.2021.119268
   PubMed Web of Science ®Google Scholar
• Jang K, Kim MK, Oh J, et al. Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers. Drug Des Devel Ther. 2017;11:705–711. doi: 10.2147/DDDT.S124307
   PubMed Web of Science ®Google Scholar
• Chung H, Kim JM, Park JW, et al. Effects of simvastatin on pharmacokinetics and anticoagulant effects of dabigatran in healthy subjects. Pharmaceuticals (Basel). 2023;16(3):364. doi: 10.3390/ph16030364
   PubMedGoogle Scholar
• Wang X, Zhu HJ, Markowitz JS. Carboxylesterase 1-mediated drug–drug interactions between clopidogrel and simvastatin. Biological & Pharmaceutical Bulletin. 2015;38(2):292–297. doi: 10.1248/bpb.b14-00679
   PubMed Web of Science ®Google Scholar
• Markowitz JS, De Faria L, Zhang Q, et al. The influence of Cannabidiol on the pharmacokinetics of methylphenidate in healthy subjects. Med Cannabis Cannabinoids. 2022;5(1):199–206. doi: 10.1159/000527189
   PubMedGoogle Scholar
• Cressman AM, Macdonald EM, Fernandes KA, et al. A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 2015;80(4):662–669. doi: 10.1111/bcp.12682
   PubMed Web of Science ®Google Scholar
• Kristensen KE, Zhu HJ, Wang X, et al. Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. Clin Pharmacol Ther. 2014;96(6):713–722. doi: 10.1038/clpt.2014.183
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Y, Lai YS, et al. Elucidation of carboxylesterase mediated pharmacokinetic interactions between Irinotecan and oroxylin a in rats via physiologically based pharmacokinetic modeling. Pharm Res. 2023;40(11):2627–2638. doi: 10.1007/s11095-023-03590-1
   PubMed Web of Science ®Google Scholar
• Shi J, Xiao J, Wang X, et al. Plasma carboxylesterase 1 predicts methylphenidate exposure: a proof-of-concept study using plasma protein biomarker for hepatic drug metabolism. Clinical pharmacology and therapeutics. Clin Pharmacol Ther. 2022;111(4):878–885. doi: 10.1002/cpt.2486
   PubMed Web of Science ®Google Scholar
• Wang DD, Zou LW, Jin Q, et al. Bioluminescent sensor reveals that carboxylesterase 1A is a novel endoplasmic reticulum-derived serologic indicator for hepatocyte injury. ACS Sens. 2020;5(7):1987–1995. doi: 10.1021/acssensors.0c00384
   PubMed Web of Science ®Google Scholar
• Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem. 2004;47(10):2393–2404. doi: 10.1021/jm0303812
   PubMed Web of Science ®Google Scholar
• Hu W-J, Chang L, Yang Y, et al. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacol Sin. 2021;42(7):1195–1200. doi: 10.1038/s41401-020-00537-9
   PubMed Web of Science ®Google Scholar
• Li R, Liclican A, Xu Y, et al. Key metabolic enzymes involved in remdesivir activation in human lung cells. Antimicrob Agents Chemother. 2021;65(9):e0060221. doi: 10.1128/aac.00602-21
   PubMed Web of Science ®Google Scholar